Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)
This study is ongoing, but not recruiting participants.
Procter and Gamble
Information provided by:
First received: July 21, 2004
Last updated: February 15, 2017
Last verified: February 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Study Completion Date:||No date given|
|Primary Completion Date:||October 2005 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||February 15, 2017|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Smith PK, Shernan SK, Chen JC, Carrier M, Verrier ED, Adams PX, Todaro TG, Muhlbaier LH, Levy JH; PRIMO-CABG II Investigators.. Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials. J Thorac Cardiovasc Surg. 2011 Jul;142(1):89-98. doi: 10.1016/j.jtcvs.2010.08.035.